Cytognos designed, in cooperation with the EuroFlow™ group, Next Generation Flow™ monitoring solutions for Hemato-oncology: MRD panels. NGF immunophenotyping protocols for hemato-oncology include 8-color tubes, allowing precise characterization of normal, reactive and neoplastic leukocyte populations. In addition, the combination of multiple antibodies in the same fluorochrome position allows the analysis of a larger number of antibodies in a single tube. The MRD panels are of a high quality. Cytognos, S.L. complies with ISO 9001:2015 Quality Management and ISO 13485:2016 for In Vitro products and research (BCP-ALL and MM MRD panel). Cytognos S.L. products for In Vitro Diagnostic comply with Directive 98/79/EC (MM MRD panel).
Cytognos offers two types of MRD panels:
- B-Cell Precursor Acute Lymphoblastic Leukemia MRD panel (BCP-ALL MRD)
- Multiple Myeloma MRD panel (MM-MRD)
B-Cell Precursor Acute Lymphoblastic Leukemia MRD panel (BCP-ALL MRD)
Flow cytometry has an essential role in the diagnosis and classification of acute leukemias together with cytomorphology and cytochemistry, by the detection and lineage assignment of blast cells in suspected samples.
The EuroFlow™ group has designed and evaluated a set of 8-color antibody panels for the diagnosis, classification and follow-up of acute leukemias, which can be used in combination with novel Infinicyt™ tools to optimize flow cytometric multidimensional immunophenotypic characterization of blast cells. The MRD panels were designed to answer specific questions that arise at different moments of the workflow and accordingly a 8-color panel was developed to help on the identification and quantification of residual pathological B cells in BCP-ALL minimal residual disease evaluation.
The BCP-ALL MRD panel designed by EuroFlow™ comprises a fully-standardized 8–color antibody panel and laboratory procedures with the intent of reaching a sensitivity of 10-6, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)–based MRD detection. The BCP-ALL MRD panel is patented.